Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Basal Cell 14Neoplasms 4Pancreatic Neoplasms 3Skin Neoplasms 2Prostatic Neoplasms 2Ovarian Neoplasms 2Medulloblastoma 2Colorectal Neoplasms 2Chondrosarcoma 2Basal Cell Nevus Syndrome 2Urinary Bladder Neoplasms 1Unspecified Adult Solid Tumor, Protocol Specific 1Stomach Neoplasms 1Solid Cancers 1Small Cell Lung Carcinoma 1Sarcoma, Synovial 1Sarcoma, Kaposi 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Rhabdomyosarcoma 1Pancreatic Diseases 1Osteosarcoma 1Odontogenic Cysts 1Neurofibrosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasms, Unknown Primary 1Neoplasms, Basal Cell 1Neoplasms by Site 1Neoplasms by Histologic Type 1Myelodysplastic Syndromes 1

Interventions

pertuzumab 1ovcon 35 1Trastuzumab 1Rosiglitazone 1HhAntag691 1Docetaxel 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Solid Cancers × HhAntag691 × Clear all
NCT01209143 2015-06-29

A Study of Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists

Genentech, Inc.

Phase 1 Completed
52 enrolled 8 charts

Solid Cancers

Data powered by HemOnc (CC BY 4.0) Colophon âš¡